LogicBio Therapeutics Performance
| LOGCDelisted Stock | USD 2.07 0.00 0.00% |
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and LogicBio Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days LogicBio Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound technical and fundamental indicators, LogicBio Therapeutics is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 70.7 M | |
| Total Cashflows From Investing Activities | -840 K |
LogicBio |
LogicBio Therapeutics Relative Risk vs. Return Landscape
If you would invest (100.00) in LogicBio Therapeutics on January 26, 2024 and sell it today you would earn a total of 100.00 from holding LogicBio Therapeutics or generate -100.0% return on investment over 90 days. LogicBio Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than LogicBio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
LogicBio Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for LogicBio Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as LogicBio Therapeutics, and traders can use it to determine the average amount a LogicBio Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| LOGC |
Based on monthly moving average LogicBio Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of LogicBio Therapeutics by adding LogicBio Therapeutics to a well-diversified portfolio.
LogicBio Therapeutics Fundamentals Growth
LogicBio Stock prices reflect investors' perceptions of the future prospects and financial health of LogicBio Therapeutics, and LogicBio Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on LogicBio Stock performance.
| Return On Equity | -0.97 | |||
| Return On Asset | -0.3 | |||
| Profit Margin | (2.47) % | |||
| Operating Margin | (2.41) % | |||
| Current Valuation | 40.47 M | |||
| Shares Outstanding | 32.96 M | |||
| Price To Earning | (3.53) X | |||
| Price To Book | 3.29 X | |||
| Price To Sales | 6.34 X | |||
| Revenue | 5.41 M | |||
| EBITDA | (38.36 M) | |||
| Cash And Equivalents | 38.85 M | |||
| Cash Per Share | 1.18 X | |||
| Total Debt | 5.01 M | |||
| Debt To Equity | 0.54 % | |||
| Book Value Per Share | 0.48 X | |||
| Cash Flow From Operations | (19 M) | |||
| Earnings Per Share | (1.12) X | |||
| Total Asset | 62.77 M | |||
| Retained Earnings | (69.14 M) | |||
| Current Asset | 1.47 M | |||
| Current Liabilities | 1.14 M | |||
About LogicBio Therapeutics Performance
To evaluate LogicBio Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when LogicBio Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare LogicBio Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand LogicBio Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents LogicBio's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. Logicbio Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 62 people.Things to note about LogicBio Therapeutics performance evaluation
Checking the ongoing alerts about LogicBio Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for LogicBio Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| LogicBio Therapeutics is not yet fully synchronised with the market data | |
| LogicBio Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 5.41 M. Net Loss for the year was (40.03 M) with loss before overhead, payroll, taxes, and interest of (22.76 M). | |
| LogicBio Therapeutics currently holds about 38.85 M in cash with (19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.18. |
- Analyzing LogicBio Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether LogicBio Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining LogicBio Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating LogicBio Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of LogicBio Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of LogicBio Therapeutics' stock. These opinions can provide insight into LogicBio Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the LogicBio Therapeutics information on this page should be used as a complementary analysis to other LogicBio Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in LogicBio Stock
If you are still planning to invest in LogicBio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the LogicBio Therapeutics' history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |